The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase III randomized trial of niraparib versus physician’s choice in previously treated, HER2-negative, germline-BRCA mutated breast cancer patients: Intergroup study EORTC-1307-BCG and BIG5-13.
Konstantinos Tryfonidis
No relevant relationships to disclose
Jan Bogaerts
No relevant relationships to disclose
Robert E. Martell
No relevant relationships to disclose
George W. Sledge
No relevant relationships to disclose
Judith Balmaña
No relevant relationships to disclose
M. William Audeh
Consultant or Advisory Role - Tesaro
Angelique Deleersnijder
No relevant relationships to disclose
Felicia Favorito
No relevant relationships to disclose
Shefali Agarwal
Stock Ownership - Tesaro
Giovanna Rizzetto
No relevant relationships to disclose
Carlo G. M. Messina
No relevant relationships to disclose
Leen Slaets
No relevant relationships to disclose
Theodora Goulioti
No relevant relationships to disclose
Andrew Tutt
No relevant relationships to disclose
David A. Cameron
No relevant relationships to disclose
Nicholas C. Turner
Consultant or Advisory Role - Tesaro